Description
Dimefosfon Pharmacodynamics
Dimefosfon shows antiacidotic, membrane stabilizing, anti-inflammatory and antioxidant properties, normalizes blood flow and metabolism of brain tissue, reduces heart and lung failure, improves the regulation of blood circulation, including the brain.
Antiacidotic action is realized through the intensification of renal and pulmonary mechanisms of regulation of acid-base status, increasing intraorganic blood flow and tissue metabolism, as well as dimefosfon reduces lactic and pyruvic acids in the brain tissue.
Dimefosfon stabilizes cell membranes, restoring the reactivity of cerebral vessels, improving the function of the large hemispheres and brain stem, reduces the depth of impairment of consciousness, restores the sleep-wake cycle, reflexes whose arcs are closed through the stem sections, reduces the severity of pyramidal, cerebellar, vestibular, visual and auditory disorders.
Antioxidant effect is achieved by preventing the activation of lipid peroxidation and increasing the activity of antioxidant enzymes in the brain tissue.
Dimefosfon enhances energy processes in the brain both directly, affecting directly the mitochondria and indirectly by stimulating the pituitary-thyroid system, increasing tissue consumption of thyroid hormones, which is accompanied by activation of energy and catabolic processes in the mitochondria of cells. Exhibits properties of some neurotransmitters. (GABA-positive, N-choline and dopaminergic activity).
Dimefosfon reduces cardiac and pulmonary insufficiency by restoring the resistance of peripheral vessels (arterial and venous).
Dimefosfon improves the regulation of cerebral circulation without a pronounced vasodilator effect, but has a positive effect on the metabolism of brain tissue during ischemia, improves venous outflow. The effectiveness of the clinical use of the drug in various forms of cerebrovascular failure is associated with its ability to increase the resistance of nerve cells to ischemia, with a decrease in edema and thereby improve microcirculation.
When topically applied dimefosfon has anti-inflammatory and antiseptic effects, increases the protective functions of the skin and mucous membranes.
Antiacidotic action is realized through the intensification of renal and pulmonary mechanisms of regulation of acid-base status, increasing intraorganic blood flow and tissue metabolism, as well as dimefosfon reduces lactic and pyruvic acids in the brain tissue.
Dimefosfon stabilizes cell membranes, restoring the reactivity of cerebral vessels, improving the function of the large hemispheres and brain stem, reduces the depth of impairment of consciousness, restores the sleep-wake cycle, reflexes whose arcs are closed through the stem sections, reduces the severity of pyramidal, cerebellar, vestibular, visual and auditory disorders.
Antioxidant effect is achieved by preventing the activation of lipid peroxidation and increasing the activity of antioxidant enzymes in the brain tissue.
Dimefosfon enhances energy processes in the brain both directly, affecting directly the mitochondria and indirectly by stimulating the pituitary-thyroid system, increasing tissue consumption of thyroid hormones, which is accompanied by activation of energy and catabolic processes in the mitochondria of cells. Exhibits properties of some neurotransmitters. (GABA-positive, N-choline and dopaminergic activity).
Dimefosfon reduces cardiac and pulmonary insufficiency by restoring the resistance of peripheral vessels (arterial and venous).
Dimefosfon improves the regulation of cerebral circulation without a pronounced vasodilator effect, but has a positive effect on the metabolism of brain tissue during ischemia, improves venous outflow. The effectiveness of the clinical use of the drug in various forms of cerebrovascular failure is associated with its ability to increase the resistance of nerve cells to ischemia, with a decrease in edema and thereby improve microcirculation.
When topically applied dimefosfon has anti-inflammatory and antiseptic effects, increases the protective functions of the skin and mucous membranes.
Indications
Inside, as part of complex therapy:
Acute and chronic disorders of cerebral circulation, consequences of ischemic and hemorrhagic strokes, craniocerebral and neurosurgical injuries, planned neurosurgical operations, osteochondrosis, multiple sclerosis, chronic non-specific pulmonary diseases with signs of respiratory and pulmonary heart failure (the use of dimefosfone does not relieve choking attacks and does not affect the frequency of beta-adrenomimetic aerosols) Vascular dystonia of the parasympathetic type, chronic cerebrovascular insufficiency due to atherosclerosis and hypertension, migraine, Meniere’s disease, respiratory diseases, acidosis, atopic bronchial asthma and pollinosis.
Externally:
Infectious-inflammatory-allergic diseases of skin and mucous membranes: wounds, areas of sutures and places of exit of Ilizarov spokes; horny inflammation; in dermatology – complex treatment of skin diseases (acne, oily seborrhea, pink acne); prevention of radiation mucositis.
Inside, as part of complex therapy:
Acute and chronic disorders of cerebral circulation, consequences of ischemic and hemorrhagic strokes, craniocerebral and neurosurgical injuries, planned neurosurgical operations, osteochondrosis, multiple sclerosis, chronic non-specific pulmonary diseases with signs of respiratory and pulmonary heart failure (the use of dimefosfone does not relieve choking attacks and does not affect the frequency of beta-adrenomimetic aerosols) Vascular dystonia of the parasympathetic type, chronic cerebrovascular insufficiency due to atherosclerosis and hypertension, migraine, Meniere’s disease, respiratory diseases, acidosis, atopic bronchial asthma and pollinosis.
Externally:
Infectious-inflammatory-allergic diseases of skin and mucous membranes: wounds, areas of sutures and places of exit of Ilizarov spokes; horny inflammation; in dermatology – complex treatment of skin diseases (acne, oily seborrhea, pink acne); prevention of radiation mucositis.
Contraindications .
– Epilepsy;
– Chronic renal failure of degree 2-3 (creatinine clearance less than 40 ml/min);
– Children and teenagers under 18 years old (because of lack of clinical data about its use in this category of patients) with acute and chronic cerebral circulatory disorders, consequences of ischemic and hemorrhagic strokes, craniocerebral and neurosurgical traumas, elective neurosurgical operations, osteochondrosis, multiple sclerosis, chronic nonspecific lung diseases with signs of respiratory and pulmonary-heart failure, chronic cerebrovascular failure due to atherosclerosis and hypertension, migraine, Meniere’s disease;
– Children under 12 years of age with vegetovascular dystonia of the parasympathetic type.
– Epilepsy;
– Chronic renal failure of degree 2-3 (creatinine clearance less than 40 ml/min);
– Children and teenagers under 18 years old (because of lack of clinical data about its use in this category of patients) with acute and chronic cerebral circulatory disorders, consequences of ischemic and hemorrhagic strokes, craniocerebral and neurosurgical traumas, elective neurosurgical operations, osteochondrosis, multiple sclerosis, chronic nonspecific lung diseases with signs of respiratory and pulmonary-heart failure, chronic cerebrovascular failure due to atherosclerosis and hypertension, migraine, Meniere’s disease;
– Children under 12 years of age with vegetovascular dystonia of the parasympathetic type.
How to use and dosages
- Dimefosfon is used internally after meals with water.
- The course of treatment depends on the nature of the disease and lasts from 3 days to 2 months.
- In the complex therapy of the following diseases and conditions:
- In acute and chronic stroke, the consequences of ischemic and hemorrhagic strokes, craniocerebral and neurosurgical trauma in adults, 15 ml (1 tablespoon) 3-4 times a day. Course duration of 2-3 weeks, in some cases up to 6 weeks.
- With planned neurosurgery 15 ml (1 tablespoon) for 5 days before and 2 months after surgery.
- In osteochondrosis in adults, 10 ml (1 dessert spoon) 3-4 times a day for 2-3 weeks, the improvement is observed on the 8-10 day treatment.
- In multiple sclerosis in adults, 100 mg/kg (45 ml) a day – 15 ml (1 tablespoon) 3 times a day for 10 days in the autumn-spring period monthly.
- In chronic nonspecific lung diseases with signs of respiratory and pulmonary-heart failure in adults – 15 ml (1 tablespoon) 3-4 times a day. The course of treatment is 7-10 days.
- Use dimefosfon does not relieve choking attacks and does not affect the frequency of use of beta-adrenomimetic aerosols.
- In case of vegetovascular dystonia of parasympathetic type, adults – 15 ml (1 tablespoon) 3 times a day for 2-3 weeks, children over 12 years old – 50 mg/kg (10-15 ml) 3 times a day for 3 weeks.
- In chronic cerebrovascular failure due to atherosclerosis and hypertension, 15 ml (1 tablespoon) 3 times a day for 2-3 weeks.
- With migraine 15 ml (1 tablespoon) 3 times a day for 2-3 weeks.
- With Meniere’s disease 15 ml (1 tablespoon) 3 times a day for 3 weeks.
- In case of respiratory diseases, acidosis, atonic bronchial asthma and pollinosis, 15-25 ml for adults, 15-25 ml for children, children are prescribed in dose 75-100 mg/kg: children under 3 – 5 ml (1 teaspoon), 3-8 years – 10 ml (1 dessert spoon), over 8 years – 15 ml (1 tablespoon) 3 times a day, with severe course – 4 times a day for 4-5 weeks.
- When atonic bronchial asthma combined with pollinosis is prescribed for 2-3 weeks before the onset of deterioration and taken throughout the flowering period. For dosing, you can use the measuring cup enclosed in the package.
- Externally
In infectious-inflammatory-allergic diseases of the skin and mucous membranes in the form of bandages, turundas and lotions with the solution daily for 3-14 days.
In the complex treatment of acne disease wipe the skin 3-4 times a day, in the evening – lotions. - With rye – lubricate the area of inflammation 3 times a day for 3-5 days.
On the area of sutures and places of Ilizarov’s spokes exit gauze napkins impregnated with dimefosfon are applied daily for 7-14 days. - For prevention of radiation mucositis – gauze wipes soaked in dimefosfon are placed in the projection of the radiation beams 20 minutes before exposure of the dose.
